Cell and gene therapy products are notoriously complex and difficult to characterize, yet early and thorough characterization is key to minimizing safety issues and the risk of holds on clinical trials. Mission Bio's Tapestri Platform is a single-cell DNA sequencing and multi-omics solution that can process 1000s of individual cells in a single assay. Powered by innovative microfluidics technology, Tapestri enables the simultaneous characterization of multiple attributes of cell and gene therapy products — including transduction/ transfection efficiency, vector copy number, on-/ off-target gene editing, multiplex editing, zygosity, and rare chromosomal aberrations. With this high-resolution data, you will gain a richer picture of genotypic and phenotypic heterogeneity than is provided by conventional bulk assays — without the need for multiple instruments or time-consuming cell culture.
In order to integrate single-cell technology quickly and easily into your analytical workflows, we offer custom assay development through our Pharma Assay Development team. With this end-to-end service, our expert team of scientists and bioinformaticians will develop the assay— from experimental design through analysis — while working closely with you to ensure every need is met. We will then transfer the assay to your institution or a qualified CRO/CDMO of your choice. To learn more, please visit www.missionbio.com/cgt, or come by booth 548 to chat!